Safety Alerts & Recalls

What does this mean?

The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as Actonel Plus Calcium. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use.

Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time.

For more information, please visit:

http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm

Early communication of ongoing safety review

The US FDA has issued an early communication about the ongoing review of new safety data for bisphosphanate medicines such as Actonel Plus Calcium. The communication was issued by the FDA after it received reports of abnormal heart rhythms that may have been associated with bisphosphanate use.

Upon initial review, it is unclear how this data should be interpreted. Therefore, FDA does not believe that healthcare providers or patients should change either their prescribing practices or their use of bisphosphonates at this time.

For more information, please visit: more information here

Source: FDA
Publication Date: 2007-10-01
Last Updated: 2009-12-06

Visit the medication page for the following drugs:

Share your story Share your story! Tell us how MediGuard has helped you or someone you love. Mobile graphic Download the MediGuard Mobile App to manage your prescription and over-the-counter medications, for free. Registration Info Taking multiple medications puts you at risk for possible drug-drug interactions Registration Info Monitor the medical treatment of you and your loved ones.